Breast cancer (invasive) · line 1 · Abemaciclib adjuvant (HR+/HER2- early high-risk breast cancer)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-ABEMACICLIB-ADJUVANT`

ID	`IND-BREAST-HR-POS-EARLY-ADJ-CDK46I`
Type	Indication
Status	reviewed 2026-05-09 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-MONARCHE-JOHNSTON-2023` `SRC-NCCN-BREAST-2025`

Notes

STUB — pending Co-Lead sign-off. REG-ABEMACICLIB-ADJUVANT created alongside this indication (abemaciclib 150 mg PO BID x 2 years; new file). CI-PREGNANCY-TERATOGEN not yet created; teratogenicity captured in do_not_do bullets instead — hard_contraindications left empty pending CI entity creation. NATALEE (ribociclib 400 mg 3w/1w-off x 3 years adjuvant; NCCN Cat 1) is an alternative adjuvant CDK4/6i; not modeled here — separate indication needed.

Used By

Algorithms

ALGO-BREAST-1L - ALGO-BREAST-1L

Indication

IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB - IND-BREAST-HR-POS-EARLY-ADJ-RIBOCICLIB